Intercell expands into mAB market
Vienna – Austria’s Intercell AG has closed the acquisition of Cytos’ platform technology for monoclonal antibody discovery, which is based on expression cloning of monoclonal antibodies from human B-cells. As per agreed terms, the first installment of a10m of the purchase price has been already paid. The second installment of a5m is unconditional, and is due at the end of next January. With the licensing agreement, Intercell says it intends to complement its Antigen Identification Program (AIP®). The deal could provide a viable basis for the development of novel and more powerful prophylactic and therapeutic vaccines, as well as antibody treatments. The company says it also opens up novel medical and commercially relevant applications for AIP®, which has been successfully applied in the identification of a large number of novel antigens from several pathogenic organisms.